Manganese exposure induces parkinsonism-like symptoms by Serpina3n-TFEB-v/p-ATPase signaling mediated lysosomal

Huihui Hong1, Sicheng Liu1, Ting Yang2

  • 1Department of Environmental Medicine, School of Medicine, Chongqing University, Chongqing, China.

PubMed

Insights

Manganese (Mn) overexposure causes parkinsonism. Removing Serpina3n protein in mice reduced Mn neurotoxicity and improved motor function by enhancing α-synuclein clearance and lysosomal function.

Area of Science:

  • Neuroscience
  • Toxicology
  • Cell Biology

Background:

  • Manganese (Mn) overexposure is linked to neurodegenerative diseases, causing parkinsonism with symptoms similar to Parkinson's disease (PD).
  • Astrocytes clear extracellular α-synuclein (α-Syn), but Mn-induced neurotoxicity mechanisms, especially involving astrocyte-expressed Serpina3n, remain unclear.
  • Serpina3n's role in Mn neurotoxicity and PD pathogenesis is unknown, necessitating investigation into its contribution to these conditions.

Purpose of the Study:

  • To elucidate the role of Serpina3n in manganese neurotoxicity and parkinsonism pathogenesis.
  • To investigate how Serpina3n influences astrocyte function, α-synuclein clearance, and lysosomal activity in the context of Mn exposure.

Main Methods:

  • Utilized wild-type and Serpina3n knockout (KO) mice subjected to chronic manganese chloride (MnCl2) intraperitoneal injections.
  • Conducted behavioral tests (open field, suspension, pole-climbing) to assess motor deficits.
  • Employed immunohistochemistry, Western blot, immunofluorescence, and quantitative real-time PCR to analyze midbrain changes, protein expression, and cellular mechanisms.

Main Results:

  • Serpina3n KO significantly alleviated Mn neurotoxicity, attenuating dopaminergic neuron damage and improving motor deficits in mice.
  • Serpina3n deficiency enhanced astrocytic α-synuclein clearance by suppressing Mn-induced lysosomal dysfunction.
  • Reduced transcription factor EB (TFEB)-v/p-ATPase signaling was identified as responsible for impaired lysosomal acidity in Mn-treated cells.

Conclusions:

  • Serpina3n acts as a detrimental factor in manganese neurotoxicity contributing to parkinsonism.
  • Serpina3n plays a novel role in regulating lysosomal function and α-synuclein clearance.
  • Targeting Serpina3n presents a potential therapeutic strategy for counteracting manganese neurotoxicity and treating parkinsonism.

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
37